In a network meta-analysis comparing SGLT2 inhibitors with GLP1-RAs in participants with diabetes and CKD, SGLT2 inhibitors had a lower risk of major CV events, supporting their implementation as first-choice therapy in people with diabetes and CKD for CV prevention purposes [95]. Here, GLP1R is linked to diabetes mellitus.